1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Diagnosis, Treatment, and Prevention of Urinary Tract Infection

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Authors: Paula Pietrucha-Dilanchian1, Thomas M. Hooton2
  • Editors: Matthew A. Mulvey3, Ann E. Stapleton4, David J. Klumpp5
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136; 2: Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136; 3: University of Utah, Salt Lake City, UT; 4: University of Washington, Seattle, WA; 5: Northwestern University, Chicago, IL
  • Source: microbiolspec December 2016 vol. 4 no. 6 doi:10.1128/microbiolspec.UTI-0021-2015
  • Received 02 November 2015 Accepted 14 November 2016 Published 16 December 2016
  • Thomas M. Hooton, thooton@med.miami.edu
image of Diagnosis, Treatment, and Prevention of Urinary Tract Infection
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Diagnosis, Treatment, and Prevention of Urinary Tract Infection, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/4/6/UTI-0021-2015-1.gif /docserver/preview/fulltext/microbiolspec/4/6/UTI-0021-2015-2.gif
  • Abstract:

    UTI may involve the lower or upper urinary tract and may be uncomplicated or complicated. The emphasis of this chapter is uncomplicated UTI. The diagnosis of uncomplicated cystitis (bladder infection) and pyelonephritis (kidney infection) is usually easily made based on the clinical presentation, whereas the diagnosis in patients with complicated UTI is often more complex. Thus uncomplicated cystitis is usually manifested by dysuria, frequency and/or urgency without fever, and pyelonephritis is usually manifested by fever and back pain/costovertebral angle tenderness. However, pyuria is usually present with UTI, regardless of location, and its absence suggests that another condition may be causing the patient’s symptoms. Treatment of cystitis is usually straightforward with one of several effective short-course antimicrobial regimens, although antimicrobial resistance continues to increase and can complicate treatment choices in certain areas. Likewise, antimicrobial resistance has complicated our management of uncomplicated pyelonephritis since resistance of uropathogens to the fluoroquinolone class, the mainstay of oral treatment for pyelonephritis, is increasing worldwide, and some of the other agents used for cystitis are not recommended for pyelonephritis due to low tissue levels. The goal of prevention of recurrent cystitis is to minimize the use of antimicrobials and there are several research efforts in progress to develop effective and safe antimicrobial-sparing preventive approaches for this common condition.

  • Citation: Pietrucha-Dilanchian P, Hooton T. 2016. Diagnosis, Treatment, and Prevention of Urinary Tract Infection. Microbiol Spectrum 4(6):UTI-0021-2015. doi:10.1128/microbiolspec.UTI-0021-2015.

Key Concept Ranking

Urinary Tract Infections
0.75630903
Bacterial Vaccines
0.62014997
Infectious Diseases
0.56800985
Asymptomatic Bacteriuria
0.5444134
0.75630903

References

1. Stamm WE, Hooton TM. 1993. Management of urinary tract infections in adults. N Engl J Med 329:1328–1334. [PubMed]
2. Gupta K, Trautner B. 2012. In the clinic. Urinary tract infection. Ann Intern Med 156:ITC3-1–ITC3-15. [PubMed]
3. Huppert JS, Biro F, Lan D, Mortensen JE, Reed J, Slap GB. 2007. Urinary symptoms in adolescent females: STI or UTI? J Adolesc Health 40:418–424. [PubMed]
4. Prentiss KA, Newby PK, Vinci RJ. 2011. Adolescent female with urinary symptoms: a diagnostic challenge for the pediatrician. Pediatr Emerg Care 27:789–794. [PubMed]
5. Hooton TM, Scholes D, Hughes JP, Winter C, Roberts PL, Stapleton AE, Stergachis A, Stamm WE. 1996. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 335:468–474. [PubMed]
6. Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. 2000. Risk factors for recurrent UTI in young women. J Infect Dis 182:1177–1182. [PubMed]
7. Gupta K, Hooton TM, Roberts PL, Stamm WE. 2001. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 135:9–16. [PubMed]
8. Scholes D, Hawn TR, Roberts PL, Li SS, Stapleton AE, Zhao LP, Stamm WE, Hooton TM. 2010. Family history and risk of recurrent cystitis and pyelonephritis in women. J Urol 184:564–569. [PubMed]
9. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. 2002. Does this woman have an acute uncomplicated urinary tract infection? JAMA 287:2701–2710. [PubMed]
10. Nicolle LE. 2008. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Clin North Am 35:1–12. [PubMed]
11. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, Infectious Diseases Society of America, American Society of Nephrology, American Geriatric Society. 2005. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 40:643–654. [PubMed]
12. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE, Infectious Diseases Society of America. 2010. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 50:625–663. [PubMed]
13. Lipsky BA. 1989. Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med 110:138–150. [PubMed]
14. Hooton TM. 2012. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 366:1028–1037. [PubMed]
15. Stamm WE, Counts GW, Running KR, Fihn S, Turck M, Holmes KK. 1982. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med 307:463–468. [PubMed]
16. Baerheim A, Digranes A, Hunskaar S. 1992. Evaluation of urine sampling technique: bacterial contamination of samples from women students. Br J Gen Pract 42:241–243. [PubMed]
17. Lifshitz E, Kramer L. 2000. Outpatient urine culture: does collection technique matter? Arch Intern Med 160:2537–2540. [PubMed]
18. Schneeberger C, van den Heuvel ER, Erwich JJ, Stolk RP, Visser CE, Geerlings SE. 2013. Contamination rates of three urine-sampling methods to assess bacteriuria in pregnant women. Obstet Gynecol 121:299–305. [PubMed]
19. Lipsky BA, Ireton RC, Fihn SD, Hackett R, Berger RE. 1987. Diagnosis of bacteriuria in men: specimen collection and culture interpretation. J Infect Dis 155:847–854. [PubMed]
20. Marple CD. 1941. The frequency and character of urinary tract infections in an unselected group of women. Ann Intern Med 14:2220–2239.
21. Barr RH, Rantz LA. 1948. The incidence of unsuspected urinary tract infection in a selected group of ambulatory women. Calif Med 68:437–440. [PubMed]
22. Kass EH. 1956. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians 69:56–64. [PubMed]
23. Kass EH. 1960. The role of asymptomatic bacteriuria in the pathogenesis of pyelonephritis, p 399–412. In Quinn EL, Kass EH (ed), Biology of Pyelonephritis. Little, Brown, Boston, MA.
24. Kass EH. 1960. Bacteriuria and pyelonephritis of pregnancy. Arch Intern Med 105:194–198. [PubMed]
25. Kass EH. 1962. Pyelonephritis and bacteriuria. A major problem in preventive medicine. Ann Intern Med 56:46–53. [PubMed]
26. Norden CW, Kass EH. 1968. Bacteriuria of pregnancy: a critical appraisal. Annu Rev Med 19:431–470. [PubMed]
27. Sanford JP, Favour CB, Mao FH, Harrison JH. 1956. Evaluation of the positive urine culture; an approach to the differentiation of significant bacteria from contaminants. Am J Med 20:88–93. [PubMed]
28. Monzon OT, Ory EM, Dobson HL, Carter E, Yow EM. 1958. A comparison of bacterial counts of the urine obtained by needle aspiration of the bladder, catheterization and midstream-voided methods. N Engl J Med 259:764–767. [PubMed]
29. Gallagher DJ, Montgomerie JZ, North JD. 1965. Acute infections of the urinary tract and the urethral syndrome in general practice. BMJ 1:622–626. [PubMed]
30. Mabeck CE. 1969. Studies in urinary tract infections. I. The diagnosis of bacteriuria in women. Acta Med Scand 186:35–38. [PubMed]
31. Stamey TA, Timothy M, Millar M, Mihara G. 1971. Recurrent urinary infections in adult women. The role of introital enterobacteria. Calif Med 115:1–19. [PubMed]
32. Hooton TM, Roberts PL, Cox ME, Stapleton AE. 2013. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med 369:1883–1891. [PubMed]
33. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE, Infectious Diseases Society of America and the Food and Drug Administration. 1992. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis 15(Suppl 1):S216–S227. [PubMed]
34. Bergqvist D, Brönnestam R, Hedelin H, Ståhl A. 1980. The relevance of urinary sampling methods in patients with indwelling Foley catheters. Br J Urol 52:92–95. [PubMed]
35. Tenney JH, Warren JW. 1988. Bacteriuria in women with long-term catheters: paired comparison of indwelling and replacement catheters. J Infect Dis 157:199–202. [PubMed]
36. Raz R, Schiller D, Nicolle LE. 2000. Chronic indwelling catheter replacement before antimicrobial therapy for symptomatic urinary tract infection. J Urol 164:1254–1258.
37. Arav-Boger R, Leibovici L, Danon YL. 1994. Urinary tract infections with low and high colony counts in young women. Spontaneous remission and single-dose vs multiple-day treatment. Arch Intern Med 154:300–304.
38. Stark RP, Maki DG. 1984. Bacteriuria in the catheterized patient. What quantitative level of bacteriuria is relevant? N Engl J Med 311:560–564. [PubMed]
39. Lehmann LE, Hauser S, Malinka T, Klaschik S, Weber SU, Schewe JC, Stüber F, Book M. 2011. Rapid qualitative urinary tract infection pathogen identification by SeptiFast real-time PCR. PLoS One 6:e17146. doi:10.1371/journal.pone.0017146. [PubMed]
40. Lehmann LE, Hauser S, Malinka T, Klaschik S, Stüber F, Book M. 2010. Real-time polymerase chain-reaction detection of pathogens is feasible to supplement the diagnostic sequence for urinary tract infections. BJU Int 106:114–120. [PubMed]
41. Köser CU, Holden MT, Ellington MJ, Cartwright EJ, Brown NM, Ogilvy-Stuart AL, Hsu LY, Chewapreecha C, Croucher NJ, Harris SR, Sanders M, Enright MC, Dougan G, Bentley SD, Parkhill J, Fraser LJ, Betley JR, Schulz-Trieglaff OB, Smith GP, Peacock SJ. 2012. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N Engl J Med 366:2267–2275. [PubMed]
42. Török ME, Reuter S, Bryant J, Köser CU, Stinchcombe SV, Nazareth B, Ellington MJ, Bentley SD, Smith GP, Parkhill J, Peacock SJ. 2013. Rapid whole-genome sequencing for investigation of a suspected tuberculosis outbreak. J Clin Microbiol 51:611–614. [PubMed]
43. Stamm WE. 1983. Measurement of pyuria and its relation to bacteriuria. Am J Med 75(1B):53–58.
44. Hooton TM, Stamm WE. 1997. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 11:551–581.
45. St John A, Boyd JC, Lowes AJ, Price CP. 2006. The use of urinary dipstick tests to exclude urinary tract infection: a systematic review of the literature. Am J Clin Pathol 126:428–436. [PubMed]
46. Little P, Turner S, Rumsby K, Jones R, Warner G, Moore M, Lowes JA, Smith H, Hawke C, Leydon G, Mullee M. 2010. Validating the prediction of lower urinary tract infection in primary care: sensitivity and specificity of urinary dipsticks and clinical scores in women. Br J Gen Pract 60:495–500. [PubMed]
47. Hurlbut TA III, Littenberg B. 1991. The diagnostic accuracy of rapid dipstick tests to predict urinary tract infection. Am J Clin Pathol 96:582–588. [PubMed]
48. Devillé WL, Yzermans JC, van Duijn NP, Bezemer PD, van der Windt DA, Bouter LM. 2004. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. BMC Urol 4:4. [PubMed]
49. Patel HD, Livsey SA, Swann RA, Bukhari SS. 2005. Can urine dipstick testing for urinary tract infection at point of care reduce laboratory workload? J Clin Pathol 58:951–954. [PubMed]
50. Giesen LG, Cousins G, Dimitrov BD, van de Laar FA, Fahey T. 2010. Predicting acute uncomplicated urinary tract infection in women: a systematic review of the diagnostic accuracy of symptoms and signs. BMC Fam Pract 11:78. [PubMed]
51. McIsaac WJ, Moineddin R, Ross S. 2007. Validation of a decision aid to assist physicians in reducing unnecessary antibiotic drug use for acute cystitis. Arch Intern Med 167:2201–2206. [PubMed]
52. Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. 2002. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 52:729–734. [PubMed]
53. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ. 2007. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. Scand J Prim Health Care 25:49–57. [PubMed]
54. Foxman B, Frerichs RR. 1985. Epidemiology of urinary tract infection: I. Diaphragm use and sexual intercourse. Am J Public Health 75:1308–1313. [PubMed]
55. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103–e120. [PubMed]
56. Paterson DL. 2004. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 38(Suppl 4):S341–S345. [PubMed]
57. Gupta K, Hooton TM, Miller L, Uncomplicated UTI IDSA Guideline Committee. 2011. Managing uncomplicated urinary tract infection: making sense out of resistance data. Clin Infect Dis 53:1041–1042. [PubMed]
58. Richards DA, Toop LJ, Chambers ST, Sutherland MG, Harris BH, Ikram RB, Jones MR, McGeoch GR, Peddie B. 2002. Antibiotic resistance in uncomplicated urinary tract infection: problems with interpreting cumulative resistance rates from local community laboratories. N Z Med J 115:12–14. [PubMed]
59. Ti TY, Kumarasinghe G, Taylor MB, Tan SL, Ee A, Chua C, Low A. 2003. What is true community-acquired urinary tract infection? Comparison of pathogens identified in urine from routine outpatient specimens and from community clinics in a prospective study. Eur J Clin Microbiol Infect Dis 22:242–245. [PubMed]
60. Baerheim A, Digranes A, Hunskaar S. 1999. Are resistance patterns in uropathogens published by microbiological laboratories valid for general practice? APMIS 107:676–680. [PubMed]
61. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, Johnson J, Noreddin A, Low DE, Karlowsky JA, Hoban DJ, NAUTICA Group. 2006. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 27:468–475. [PubMed]
62. Naber KG, Schito G, Botto H, Palou J, Mazzei T. 2008. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 54:1164–1175. [PubMed]
63. Wagenlehner FM, Hoyme U, Kaase M, Fünfstück R, Naber KG, Schmiemann G. 2011. Uncomplicated urinary tract infections. Dtsch Arztebl Int 108:415–423. [PubMed]
64. Brown PD, Freeman A, Foxman B. 2002. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 34:1061–1066. [PubMed]
65. Metlay JP, Strom BL, Asch DA. 2003. Prior antimicrobial drug exposure: a risk factor for trimethoprim-sulfamethoxazole-resistant urinary tract infections. J Antimicrob Chemother 51:963–970. [PubMed]
66. Colgan R, Johnson JR, Kuskowski M, Gupta K. 2008. Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis. Antimicrob Agents Chemother 52:846–851. [PubMed]
67. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. 2012. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 56:2181–2183. [PubMed]
68. Omigie O, Okoror L, Umolu P, Ikuuh G. 2009. Increasing resistance to quinolones: a four-year prospective study of urinary tract infection pathogens. Int J Gen Med 2:171–175. [PubMed]
69. Olson RP, Harrell LJ, Kaye KS. 2009. Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections. Antimicrob Agents Chemother 53:1285–1286. [PubMed]
70. Nicolle LE. 2011. Update in adult urinary tract infection. Curr Infect Dis Rep 13:552–560. [PubMed]
71. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. 2009. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 34:407–413. [PubMed]
72. Ho PL, Yip KS, Chow KH, Lo JY, Que TL, Yuen KY. 2010. Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008. Diagn Microbiol Infect Dis 66:87–93. [PubMed]
73. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. 2011. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 39:333–340. [PubMed]
74. Peirano G, Pitout JD. 2010. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 35:316–321. [PubMed]
75. Peirano G, Laupland KB, Gregson DB, Pitout JD. 2011. Colonization of returning travelers with CTX-M-producing Escherichia coli. J Travel Med 18:299–303. [PubMed]
76. Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, Athanasiou S. 2010. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 65:1862–1877. [PubMed]
77. Prakash V, Lewis JS II, Herrera ML, Wickes BL, Jorgensen JH. 2009. Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother 53:1278–1280. [PubMed]
78. Auer S, Wojna A, Hell M. 2010. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 54:4006–4008. [PubMed]
79. Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A. 2008. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 168:1897–1902. [PubMed]
80. Milo G, Katchman EA, Paul M, Christiaens T, Baerheim A, Leibovici L. 2005. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev (2):CD004682. [PubMed]
81. Lutters M, Vogt-Ferrier NB. 2008. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev (3):CD001535. [PubMed]
82. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE, Infectious Diseases Society of America (IDSA). 1999. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 29:745–758. [PubMed]
83. De Zeeuw J, Schumacher J, Gillissen AG. 2012. Nitrofurantoin-induced pulmonary injury. http://www.uptodate.com/contents/nitrofurantoin-induced-pulmonary-injury.
84. Gupta K, Hooton TM, Roberts PL, Stamm WE. 2007. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 167:2207–2212. [PubMed]
85. Reynolds TD, Thomas J. 2013. Nitrofurantoin related pulmonary disease: a clinical reminder. BMJ Case Rep 2013:bcr2013009299. doi:10.1136/bcr-2013-009299. [PubMed]
86. Madani Y, Mann B. 2012. Nitrofurantoin-induced lung disease and prophylaxis of urinary tract infections. Prim Care Respir J 21:337–341. [PubMed]
87. Williams EM, Triller DM. 2006. Recurrent acute nitrofurantoin-induced pulmonary toxicity. Pharmacotherapy 26:713–718. [PubMed]
88. Mendez JL, Nadrous HF, Hartman TE, Ryu JH. 2005. Chronic nitrofurantoin-induced lung disease. Mayo Clin Proc 80:1298–1302. [PubMed]
89. Williams EM, Triller DM. 2006. Recurrent acute nitrofurantoin-induced pulmonary toxicity. Pharmacotherapy 26:713–718. [PubMed]
90. Harrabi H. 2012. Uncomplicated urinary tract infection. N Engl J Med 367:185, author reply 185. [PubMed]
91. Campanelli CM, American Geriatrics Society 2012 Beers Criteria Update Expert Panel. 2012. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60:616–631. [PubMed]
92. Guay DR. 2001. An update on the role of nitrofurans in the management of urinary tract infections. Drugs 61:353–364. [PubMed]
93. Oplinger M, Andrews CO. 2013. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. Ann Pharmacother 47:106–111. [PubMed]
94. Geerts AF, Eppenga WL, Heerdink R, Derijks HJ, Wensing MJ, Egberts TC, De Smet PA. 2013. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol 69:1701–1707. [PubMed]
95. Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, Lavi I, Stamm W, Israeli Urinary Tract Infection Group. 2002. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 34:1165–1169. [PubMed]
96. Hooton TM. 2003. The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am 17:303–332. [PubMed]
97. Gupta K, Hooton TM, Stamm WE. 2001. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 135:41–50. [PubMed]
98. Kallen AJ, Welch HG, Sirovich BE. 2006. Current antibiotic therapy for isolated urinary tract infections in women. Arch Intern Med 166:635–639. [PubMed]
99. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254–1260. [PubMed]
100. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. 2005. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 293:949–955. [PubMed]
101. Hooton TM, Roberts PL, Stapleton AE. 2012. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 307:583–589. [PubMed]
102. Klimberg I, Shockey G, Ellison H, Fuller-Jonap F, Colgan R, Song J, Keating K, Cyrus P. 2005. Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study. Curr Med Res Opin 21:1241–1250. [PubMed]
103. Little P, Moore MV, Turner S, Rumsby K, Warner G, Lowes JA, Smith H, Hawke C, Leydon G, Arscott A, Turner D, Mullee M. 2010. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ 340:c199. [PubMed]
104. Leydon GM, Turner S, Smith H, Little P, UTIS Team. 2010. Women’s views about management and cause of urinary tract infection: qualitative interview study. BMJ 340:c279. [PubMed]
105. Bleidorn J, Gágyor I, Kochen MM, Wegscheider K, Hummers-Pradier E. 2010. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? Results of a randomized controlled pilot trial. BMC Med 8:30. doi:10.1186/1741-7015-8-30.
106. Gágyor I, Hummers-Pradier E, Kochen MM, Schmiemann G, Wegscheider K, Bleidorn J. 2012. Immediate versus conditional treatment of uncomplicated urinary tract infection: a randomized-controlled comparative effectiveness study in general practices. BMC Infect Dis 12:146. doi:10.1186/1471-2334-12-146.
107. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ. 2010. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 6:e1001042. doi:10.1371/journal.ppat1001042.
108. Czaja CA, Scholes D, Hooton TM, Stamm WE. 2007. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 45:273–280. [PubMed]
109. van der Starre WE, van Dissel JT, van Nieuwkoop C. 2011. Treatment duration of febrile urinary tract infections. Curr Infect Dis Rep 13:571–578. [PubMed]
110. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J, Church DA. 2000. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 283:1583–1590. [PubMed]
111. Johnson JR, Lyons MF II, Pearce W, Gorman P, Roberts PL, White N, Brust P, Olsen R, Gnann JW Jr, Stamm WE. 1991. Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days. J Infect Dis 163:325–330. [PubMed]
112. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. 2008. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 71:17–22. [PubMed]
113. Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. 2007. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin 23:2637–2645. [PubMed]
114. Talan DA, Klimberg IW, Nicolle LE, Song J, Kowalsky SF, Church DA. 2004. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol 171:734–739. [PubMed]
115. Mombelli G, Pezzoli R, Pinoja-Lutz G, Monotti R, Marone C, Franciolli M. 1999. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med 159:53–58. [PubMed]
116. Lichtenberger P, Hooton TM. 2011. Antimicrobial prophylaxis in women with recurrent urinary tract infections. Int J Antimicrob Agents 38(Suppl):36–41. [PubMed]
117. Sobota AE. 1984. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. J Urol 131:1013–1016. [PubMed]
118. Schmidt DR, Sobota AE. 1988. An examination of the anti-adherence activity of cranberry juice on urinary and nonurinary bacterial isolates. Microbios 55:173–181. [PubMed]
119. Zafriri D, Ofek I, Adar R, Pocino M, Sharon N. 1989. Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob Agents Chemother 33:92–98. [PubMed]
120. Howell AB, Vorsa N, Der Marderosian A, Foo LY. 1998. Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. N Engl J Med 339:1085–1086. [PubMed]
121. Barbosa-Cesnik C, Brown MB, Buxton M, Zhang L, DeBusscher J, Foxman B. 2011. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis 52:23–30. [PubMed]
122. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. 2011. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med 171:1270–1278. [PubMed]
123. Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. 2001. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 322:1571. [PubMed]
124. Stothers L. 2002. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. Can J Urol 9:1558–1562. [PubMed]
125. Stapleton AE, Dziura J, Hooton TM, Cox ME, Yarova-Yarovaya Y, Chen S, Gupta K. 2012. Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin Proc 87:143–150. [PubMed]
126. Wang CH, Fang CC, Chen NC, Liu SS, Yu PH, Wu TY, Chen WT, Lee CC, Chen SC. 2012. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 172:988–996. [PubMed]
127. Jepson RG, Williams G, Craig JC. 2012. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 10:CD001321. [PubMed]
128. Eells SJ, McKinnell JA, Miller LG. 2011. Daily cranberry prophylaxis to prevent recurrent urinary tract infections may be beneficial in some populations of women. Clin Infect Dis 52:1393–1394, author reply 1394–1395. [PubMed]
129. Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D’Elia C, Malossini G, Boddi V, Bartoletti R. 2012. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis 55:771–777. [PubMed]
130. Darouiche RO, Green BG, Donovan WH, Chen D, Schwartz M, Merritt J, Mendez M, Hull RA. 2011. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology 78:341–346. [PubMed]
131. Nicolle LE, Ronald AR. 1987. Recurrent urinary tract infection in adult women: diagnosis and treatment. Infect Dis Clin North Am 1:793–806. [PubMed]
132. Hooton TM. 2001. Recurrent urinary tract infection in women. Int J Antimicrob Agents 17:259–268. [PubMed]
133. Nicolle LE. 1992. Prophylaxis: recurrent cystitis in non pregnant women. Infection 20(suppl 3):s164–s170. [PubMed]
134. Gupta K, Trautner BW. 2013. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ 346:f3140. [PubMed]
135. Ronald AR, Conway B. 1988. An approach to urinary tract infections in ambulatory women. Curr Clin Top Infect Dis 9:76–125. [PubMed]
136. Wagenlehner FM, Vahlensieck W, Bauer HW, Weidner W, Piechota HJ, Naber KG. 2013. Prevention of recurrent urinary tract infections. Minerva Urol Nefrol 65:9–20. [PubMed]
137. Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. 2004. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev (3):CD001209. [PubMed]
138. Stapleton A, Latham RH, Johnson C, Stamm WE. 1990. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo-controlled trial. JAMA 264:703–706.
139. Melekos MD, Asbach HW, Gerharz E, Zarakovitis IE, Weingaertner K, Naber KG. 1997. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol 157:935–939.
140. Pfau A, Sacks TG. 1992. Effective prophylaxis for recurrent urinary tract infections during pregnancy. Clin Infect Dis 14:810–814. [PubMed]
141. Kraft JK, Stamey TA. 1977. The natural history of symptomatic recurrent bacteriuria in women. Medicine (Baltimore) 56:55–60. [PubMed]
142. Stamm WE, McKevitt M, Roberts PL, White NJ. 1991. Natural history of recurrent urinary tract infections in women. Rev Infect Dis 13:77–84. [PubMed]
143. Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. 1988. Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. J Infect Dis 157:1239–1242. [PubMed]
144. Harding GK, Ronald AR, Nicolle LE, Thomson MJ, Gray GJ. 1982. Long-term antimicrobial prophylaxis for recurrent urinary tract infection in women. Rev Infect Dis 4:438–443. [PubMed]
145. Brumfitt W, Hamilton-Miller JM. 1998. Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years’ experience. J Antimicrob Chemother 42:363–371. [PubMed]
146. Rudenko N, Dorofeyev A. 2005. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung 55:420–427. [PubMed]
147. Wong ES, McKevitt M, Running K, Counts GW, Turck M, Stamm WE. 1985. Management of recurrent urinary tract infections with patient-administered single-dose therapy. Ann Intern Med 102:302–307. [PubMed]
148. Schaeffer AJ, Stuppy BA. 1999. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol 161:207–211.
149. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. 2012. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 172:704–712. [PubMed]
150. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Béliveau C, Oughton M, Brukner I, Dascal A. 2011. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365:1693–1703. [PubMed]
151. Blossom DB, McDonald LC. 2007. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 45:222–227. [PubMed]
152. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. 2009. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 34:407–413. [PubMed]
153. Raz R, Stamm WE. 1993. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329:753–756. [PubMed]
154. Eriksen B. 1999. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 180:1072–1079.
155. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. 2008. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev (2):CD005131. [PubMed]
156. Raz R, Colodner R, Rohana Y, Battino S, Rottensterich E, Wasser I, Stamm W. 2003. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis 36:1362–1368. [PubMed]
157. Lüthje P, Brauner H, Ramos NL, Ovregaard A, Gläser R, Hirschberg AL, Aspenström P, Brauner A. 2013. Estrogen supports urothelial defense mechanisms. Sci Transl Med 5:190ra80. [PubMed]
158. Hannan TJ, Hooton TM, Hultgren SJ. 2013. Estrogen and recurrent UTI: what are the facts? Sci Transl Med 5:190fs23. [PubMed]
159. Barrons R, Tassone D. 2008. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 30:453–468. [PubMed]
160. Grin PM, Kowalewska PM, Alhazzan W, Fox-Robichaud AE. 2013. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol 20:6607–6614. [PubMed]
161. Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, Yarova-Yarovaya Y, Fiedler T, Cox M, Stamm WE. 2011. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 52:1212–1217. [PubMed]
162. Sivick KE, Mobley HL. 2010. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun 78:568–585. [PubMed]
163. Barber AE, Norton JP, Spivak AM, Mulvey MA. 2013. Urinary tract infections: current and emerging management strategies. Clin Infect Dis 57:719–724. [PubMed]
164. Brumbaugh AR, Mobley HL. 2012. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines 11:663–676. [PubMed]
165. Martinez JJ, Mulvey MA, Schilling JD, Pinkner JS, Hultgren SJ. 2000. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 19:2803–2812. [PubMed]
166. Totsika M, Kostakioti M, Hannan TJ, Upton M, Beatson SA, Janetka JW, Hultgren SJ, Schembri MA. 2013. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J Infect Dis 208:921–928. [PubMed]
167. Chen SL, Hung CS, Pinkner JS, Walker JN, Cusumano CK, Li Z, Bouckaert J, Gordon JI, Hultgren SJ. 2009. Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proc Natl Acad Sci USA 106:22439–22444. [PubMed]
168. Han Z, Pinkner JS, Ford B, Obermann R, Nolan W, Wildman SA, Hobbs D, Ellenberger T, Cusumano CK, Hultgren SJ, Janetka JW. 2010. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 53:4779–4792. [PubMed]
169. Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Lüthi C, Scharenberg M, Bezençon J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B. 2010. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem 53:8627–8641. [PubMed]
170. Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, Crowley JR, Henderson JP, Janetka JW, Hultgren SJ. 2011. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 3:109ra115. [PubMed]
171. Kranjčec B, Papeš D, Altarac S. 2013. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol 32:79–84. [PubMed]
microbiolspec.UTI-0021-2015.citations
cm/4/6
content/journal/microbiolspec/10.1128/microbiolspec.UTI-0021-2015
Loading

Citations loading...

Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.UTI-0021-2015
2016-12-16
2017-09-23

Abstract:

UTI may involve the lower or upper urinary tract and may be uncomplicated or complicated. The emphasis of this chapter is uncomplicated UTI. The diagnosis of uncomplicated cystitis (bladder infection) and pyelonephritis (kidney infection) is usually easily made based on the clinical presentation, whereas the diagnosis in patients with complicated UTI is often more complex. Thus uncomplicated cystitis is usually manifested by dysuria, frequency and/or urgency without fever, and pyelonephritis is usually manifested by fever and back pain/costovertebral angle tenderness. However, pyuria is usually present with UTI, regardless of location, and its absence suggests that another condition may be causing the patient’s symptoms. Treatment of cystitis is usually straightforward with one of several effective short-course antimicrobial regimens, although antimicrobial resistance continues to increase and can complicate treatment choices in certain areas. Likewise, antimicrobial resistance has complicated our management of uncomplicated pyelonephritis since resistance of uropathogens to the fluoroquinolone class, the mainstay of oral treatment for pyelonephritis, is increasing worldwide, and some of the other agents used for cystitis are not recommended for pyelonephritis due to low tissue levels. The goal of prevention of recurrent cystitis is to minimize the use of antimicrobials and there are several research efforts in progress to develop effective and safe antimicrobial-sparing preventive approaches for this common condition.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Tables

Generic image for table
TABLE 1

Empiric antimicrobials for acute uncomplicated cystitis

Source: microbiolspec December 2016 vol. 4 no. 6 doi:10.1128/microbiolspec.UTI-0021-2015
Generic image for table
TABLE 2

Empiric oral antimicrobials for outpatient management of acute uncomplicated pyelonephritis

Source: microbiolspec December 2016 vol. 4 no. 6 doi:10.1128/microbiolspec.UTI-0021-2015
Generic image for table
TABLE 3

Empiric antimicrobials for inpatient management of acute uncomplicated pyelonephritis

Source: microbiolspec December 2016 vol. 4 no. 6 doi:10.1128/microbiolspec.UTI-0021-2015
Generic image for table
TABLE 4

Antimicrobials for recurrent acute uncomplicated cystitis

Source: microbiolspec December 2016 vol. 4 no. 6 doi:10.1128/microbiolspec.UTI-0021-2015

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error